video (9:15 min) Outcome of ovarian cancer patients was significantly improved with niraparib. ESMO 2016

(9:15 min) video

Dr Mansoor Raza Mirza - Copenhagen University Hospital, Copenhagen, Denmark

Dr Raza Mirza presents, at a press conference at ESMO 2016, the results of the ENGOT-OV16/NOVA trial.

They found that the PARP inhibitor niraparib significantly improved the outcome of platinum-sensitive recurrent ovarian cancer.
The trial met its primary endpoint, with niraparib considerably prolonging progression-free survival compared to placebo.
Read the news story or watch the interview for more.